Relationship between endothelial dysfunction and development of complications of metabolic syndrome

Abstract

The article presents the analysis of literature data on the pathogenetic role of endothelial dysfunction (ED) in the development of complications of metabolic syndrome (MS). There are two main signs of MS development - abdominal obesity (AO) and primary insulin resistance (IR). IR and concomitant hyperinsulinemia have both direct and indirect atherogenic effects on vascular walls, lead to the development of dyslipidemia, a number of hormonal and metabolic disorders, activation of the sympathoadrenal system, ie, are the basis of almost all components of MS. Despite the high margin of safety of the circulatory system, there comes a time when, due to frequent vasoconstrictor effects thickening of the walls of resistive vessels occurs to limit local perfusion. The thickening of the walls of arteries develops, that is, the modeling of the vascular wall occurs, leading to an increase of the total peripheral vascular resistance with normal tone of smooth muscles. Currently, the concept of ED is formulated as a key link of insulin resistance and atherogenesis in MS. Methods for studying endothelial function have been created and are introduced into clinical practice. New approaches to directed correction of endothelial dysfunction are being developed. Prospective studies have shown that the degree of endothelial dysfunction may be important in predicting cardiovascular events in patients with or without identified vascular disease. Probably, ED may also be related to the pathogenesis of diabetes mellitus type 2 (DM2). Since all components of MS can have an adverse effect on endothelium, ED can be an extremely common phenomenon in patients with metabolic syndrome and can act as a predictor of increased risk of cardiovascular diseases and DM2 in this population.

Keywords

metabolic syndrome / endothelial dysfunction / cardiovascular diseases

References

[1] Yakovlev V.M., Yagoda A.V. Metabolicheskiy sindrom i sosudistyy endoteliy. (Metabolic syndrome and vascular endothelium.) Stavropol. 2008; 208 p. (In Russ.)

[2] Яковлев В.М., Ягода А.В. Метаболический синдром и сосудистый эндотелий. Ставрополь. 2008; 208 с.

[3] Dedov I.I., Mel’nichenko G.A., Romancova T.I. Pathogenetic aspects of obesity. Ozhirenie i metabolism. 2004; (1): 3–9. (In Russ.)

[4] Дедов И.И., Мельниченко Г.А., Романцова Т.И. Патогенетические аспекты ожирения. Ожирение и метаболизм. 2004; (1): 3-9. DOI: 10.14341/2071-8713-5172.

[5] Metabolicheskiy sindrom. (Metabolic syndrome.) Ed. by G.E. Roytberg. Moscow: MED-press-inform. 2007; 224 p. (In Russ.)

[6] Метаболический синдром. Под ред. Г.Е. Ройтберга. М.: МЕД-пресс-информ. 2007; 224 с.

[7] Maskova G.S., Chernaya N.L., Dadaeva O.B. Pathogenetic variants in the development of endothelial dysfunction of blood vessels among adolescents with obesity. Vestnik novykh meditsinskikh tekhnologiy. eJournal. 2015; (4): 2–4. (In Russ.)

[8] Маскова Г.С., Черная Н.Л., Дадаева О.Б. Патогенетические варианты развития дисфункции эндотелия сосудов у подростков с ожирением. Вестник новых медицинских технологий. 2015; (4): 2-4. DOI: 10.12737/14921.

[9] Denisov E.N., Rusanova N.R. On the importance of endothelium in vascular remodeling in hypertension. Nauchnye issledovaniya: ot teorii k praktike. 2015; 4 (5): 88–89. (In Russ.)

[10] Денисов Е.Н., Русанова Н.Р. О значении эндотелия в ремоделировании сосудов при артериальной гипертензии. Научные исследования: от теории к практике. 2015; 4 (5): 88-89.

[11] Popova A.A., Mayanskaya S.D., Mayanskaya N.N. et al. Arterial hypertension and endothelial dysfunction. Vestnik sovremennoy klinicheskoy meditsiny. 2009; 2 (2): 41–46. (In Russ.)

[12] Попова А.А., Маянская С.Д., Маянская Н.Н. и др. Артериальная гипертония и дисфункция эндотелия. Вестник современной клинической медицины. 2009; 2 (2): 41-46.

[13] Tsang H., Leiper J., Hou Lao K. et al. Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function. Pulm. Circ. 2013; 3 (3): 675–691. DOI: 10.1086/674440.

[14] Tsang H., Leiper J., Hou Lao K. et al. Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function. Pulm. Circ. 2013; 3 (3): 675-691. DOI: 10.1086/674440.

[15] Ledyaev M.Ya., Chernenkov Yu.V., Cherkasov N.S. et al. Assessment of risk factors and prevention of arterial hypertension in adolescents. Lechashchiy vrach. 2012; (6): 27–31. (In Russ.)

[16] Ледяев М.Я., Черненков Ю.В., Черкасов Н.С. и др. Оценка факторов риска и профилактика развития артериальной гипертензии у подростков. Лечащий врач. 2012; (6): 27-31.

[17] Asayama K., Wei F.F., Staessen J.A. Does blood pressure variability contribute to risk stratification? Methodological issues and a review of outcome studies based on home blood pressure. Hypertens. Res. 2015; 38 (2): 97–101. DOI: 10.1038/hr.2014.153.

[18] Asayama K., Wei F.F., Staessen J.A. Does blood pressure variability contribute to risk stratification? Methodological issues and a review of outcome studies based on home blood pressure. Hypertens. Res. 2015; 38 (2): 97-101. DOI: 10.1038/hr.2014.153.

[19] Raitakari O.T., Juonala M., Kähönen M. et al. Cardiovascular risk factors in childhood and carotid artery intimamedia thickness in adult­hood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003; 290: 2277–2283. DOI: 10.1001/jama.290.17.2277.

[20] Raitakari O.T., Juonala M., Kähönen M. et al. Cardiovascular risk factors in childhood and carotid artery intimamedia thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003; 290: 2277-2283. DOI: 10.1001/jama.290.17.2277.

[21] Stryuk R.I., Brytkova Ya.V. Endothelial dysfunction is an early marker debut of arterial hypertension. Kardiovaskulyarnaya terapiya i profilaktika. 2014; 13 (2): 110. (In Russ.)

[22] Стрюк Р.И., Брыткова Я.В. Дисфункция эндотелия - ранний маркер дебюта артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2014; 13 (2): 110.

[23] Tabarov M.S., Toshtemirova Z.M., Saidmuradova R.A. et al. Physiology and pathology of the endothelium. Vestnik Avitsenny. 2012; (2): 196–202. (In Russ.)

[24] Табаров М.С., Тоштемирова З.М., Саидмурадова Р.А. и др. Физиология и патология эндотелия. Вестник Авиценны. 2012; (2): 196-202.

[25] Kardiologiya: natsional’noe rukovodstvo. (Cardiology: national guide.) Ed. by Yu.N. Belenkov, R.G. Oganov. Moscow: GEOTAR-Media. 2010; 1232 p. (In Russ.)

[26] Кардиология: национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР Медиа. 2010; 1232 с.

[27] Rheaume C., Arsenault B., Despres J. et al. Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women: the EPIC-Norfolk Population Study. J. Hypertens. 2014; 32 (11): 2224–2230. DOI: 10.1097/HJH.0000000000000307.

[28] Rheaume C., Arsenault B., Despres J. et al. Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women: the EPIC-Norfolk Population Study. J. Hypertens. 2014; 32 (11): 2224-2230. DOI: 10.1097/HJH.0000000000000307.

[29] Staessen J.A. Hypertension: Age-specificity of blood-pressure-associated complications. Nat. Rev. Cardiol. 2014; 11 (9): 499–501. DOI: 10.1038/nrcardio.2014.109.

[30] Staessen J.A. Hypertension: Age-specificity of blood-pressure-associated complications. Nat. Rev. Cardiol. 2014; 11 (9): 499-501. DOI: 10.1038/nrcardio.2014.109.

[31] Sadykova D.I., Sergeeva E.V., Aflyatumova G.N. The importance of endothelial dysfunction in hypertension in children and adolescents. Prakticheskaya meditsina. 2014; (9): 24–27. (In Russ.)

[32] Садыкова Д.И., Сергеева Е.В., Афлятумова Г.Н. Значение дисфункции эндотелия при артериальной гипертензии у детей и подростков. Практическая медицина. 2014; (9): 24-27.

[33] Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115: 1285–1295. PMID: 17353456.

[34] Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115: 1285-1295. PMID: 17353456.

[35] Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109: 27–32. DOI: 10.1161/01.CIR.0000131515.03336.f8.

[36] Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109: 27-32. DOI: 10.1161/01.CIR.0000131515.03336.f8.

[37] Verma S., Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002; 105: 546–549. DOI: 10.1161/hc0502.104540.

[38] Verma S., Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002; 105: 546-549. DOI: 10.1161/hc0502.104540.

[39] Malinovskaya A.Ya. Endothelial dysfunction in women with arterial hypertension and pathological course of menopause and the possibility of its correction with the use of combination therapy with moeksipril and diltiazem. Retsept. 2016; (1): 59–71. (In Russ.)

[40] Малиновская А.Я. Дисфункция эндотелия у женщин с артериальной гипертензией и патологическим течением климакса и возможности ее коррекции с использованием комбинированной терапии моэксиприлом и дилтиаземом. Рецепт. 2016; (1): 59-71.

[41] Willoughby S.R., Rajendran S., Chan W.P. et al. Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients. J. Am. Coll. Cardiol. 2012; 60: 887–894. DOI: 10.1016/j.jacc.2012.01.066.

[42] Willoughby S.R., Rajendran S., Chan W.P. et al. Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients. J. Am. Coll. Cardiol. 2012; 60: 887-894. DOI: 10.1016/j.jacc.2012.01.066.

[43] Rubbo H., Trostchansky A., Botti H. et al. Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. Biol. Chem. 2002; 383: 547–552. DOI: 10.1515/BC.2002.055.

[44] Rubbo H., Trostchansky A., Botti H. et al. Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. Biol. Chem. 2002; 383: 547-552. DOI: 10.1515/BC.2002.055.

[45] Inan B., Ates I., Ozkayar N. et al. Are ­increased oxidative stress and asymmetric dimethylarginine ­levels associated with masked hypertension? Clin. Exp. Hypertens. 2016; 38 (3): 294–298. DOI: 10.3109/­10641963.2015.1089883.

[46] Inan B., Ates I., Ozkayar N. et al. Are increased oxidative stress and asymmetric dimethylarginine levels associated with masked hypertension? Clin. Exp. Hypertens. 2016; 38 (3): 294-298. DOI: 10.3109/10641963.2015.1089883.

[47] Pattillo Ch.B., Bir Sh., Rajaram V., Kevil Ch.G Inorganic nitrite and chronic tissue ischaemia: a novel therapeutic modality for peripheral vascular diseases. Cardiovasc. Res. 2011; 89: 533–541. DOI: 10.1093/cvr/cvq297.

[48] Pattillo Ch.B., Bir Sh., Rajaram V., Kevil Ch.G Inorganic nitrite and chronic tissue ischaemia: a novel therapeutic modality for peripheral vascular diseases. Cardiovasc. Res. 2011; 89: 533-541. DOI: 10.1093/cvr/cvq297.

[49] Steinberg D., Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Circulation. 2002; 105: 2107–2111. DOI: 10.1161/01.CIR.0000014762.06201.06.

[50] Steinberg D., Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Circulation. 2002; 105: 2107-2111. DOI: 10.1161/01.CIR.0000014762.06201.06.

[51] Shestakova M.V. Endothelial ­dysfunction — the cause or consequence of metabolic syndrome? RMZh. 2001; 9 (2): 88–90. (In Russ.)

[52] Шестакова М.В. Дисфункция эндотелия - причина или следствие метаболического синдрома? РМЖ. 2001; 9 (2): 88-90.

[53] Mkrtumyan A.M., Biryukova E.V., Markina N.V., Garbuzova M.A. Parameters of endothelial dysfunction and insulin resistance in patients with metabolic syndrome before and after weight loss. Ozhirenie i metabolizm. 2008; (1): 18–22. (In Russ.)

[54] Мкртумян А.М., Бирюкова Е.В., Маркина Н.В., Гарбузова М.А. Параметры эндотелиальной дисфункции и инсулинорезистентности больных метаболическим синдромом до и после снижения массы тела. Ожирение и метаболизм. 2008; (1): 18-22.

[55] Balabolkin M.I. Insulin resistance and its significance in the pathogenesis of disorders of carbohydrate metabolism and diabetes type 2. Sakharnyy diabet. 2002; (1): 12–20. (In Russ.)

[56] Балаболкин М.И. Инсулинорезистентность и ее значение в патогенезе нарушений углеводного обмена и сахарного диабета типа 2. Сахарный диабет. 2002; (1): 12-20. DOI: 10.14341/2072-0351-5848.

[57] Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Res. Circ. Res. 2000; 87 (10): 840–844. PMID: 11073878.

[58] Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Res. Circ. Res. 2000; 87 (10): 840-844. PMID: 11073878.

[59] Vita J.A. Endothelial function and clinical outcome. Heart. 2005; 91: 1278–1279. DOI: 10.1136/hrt.2005.061333.

[60] Vita J.A. Endothelial function and clinical outcome. Heart. 2005; 91: 1278-1279. DOI: 10.1136/hrt.2005.061333.

[61] Watanabe S., Tagawa T., Yamakawa K. et al. Inhibition of the rennin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscleros. Thrombos. Vascul. Biol. 2005; 25: 2376–2383. DOI: 10.1161/01.ATV.0000187465.55507.85.

[62] Watanabe S., Tagawa T., Yamakawa K. et al. Inhibition of the rennin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscleros. Thrombos. Vascul. Biol. 2005; 25: 2376-2383. DOI: 10.1161/01.ATV.0000187465.55507.85.

[63] Duvall W.L. Endothelial dysfunction and antioxidants. Mt. Sinai J. Med. 2005; 72 (2): 71–80. PMID: 15770336.

[64] Duvall W.L. Endothelial dysfunction and antioxidants. Mt. Sinai J. Med. 2005; 72 (2): 71-80. PMID: 15770336.

[65] Bekezin V.V., Kovalenko O.M., Kozlova L.V. et al. Features of free-radical oxidation in children and adolescents with obesity and metabolic syndrome. Vestnik Sankt-Peterburgskoy meditsinskoy akademii. 2009; (2): 49–53. (In Russ.)

[66] Бекезин В.В., Коваленко О.М., Козлова Л.В. и др. Особенности свободнорадикального окисления у детей и подростков с ожирением и метаболическим синдромом. Вестник Санкт-Петербургской медицинской академии. 2009; (2): 49-53.

[67] Popov V.V., Bulanova N.A., Ivanov G.G. Modern targets of antihypertensive therapy. Ratsional’naya farmakoterapiya v kardiologii. 2012; 8 (1): 88–94. (In Russ.)

[68] Попов В.В., Буланова Н.А., Иванов Г.Г. Современные мишени антигипертензивной терапии. Рациональная фармакотерапия в кардиологии. 2012; 8 (1): 88-94.

[69] Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. ­Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1712–1719. DOI: 10.1161/hq1101.098486.

[70] Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1712-1719. DOI: 10.1161/hq1101.098486.

[71] Kovolenko L.V., Belova E.A., Verizhnikova L.N. Endothelial dysfunction and metabolic syndrome. Vestnik SurGU. Meditsina. 2013; (3): 8–13. (In Russ.)

[72] Коволенко Л.В., Белова Е.А., Верижникова Л.Н. Эндотелиальная дисфункция и метоболический синдром. Вестник СурГУ. Медицина. 2013; (3): 8-13.

[73] Kozlova L.V., Bekezin V.V., Alimova I.L. Effect of metformin on the cardiovascular system in children and adolescents with metabolic syndrome. Vestnik pediatricheskoy farmakologii i nutritsiologii. 2005; (4): 20–23. (In Russ.)

[74] Козлова Л.В., Бекезин В.В., Алимова И.Л. Влияние метформина на состояние сердечно-сосудистой системы у детей и подростков с метаболическим синдромом. Вестник педиатрической фармакологии и нутрициологии. 2005; (4): 20-23.

[75] Bekezin V.V. Insulin resistance and endothelial dysfunction. Their contribution to the development of metabolic syndrome in children and adolescents. Vladikavkazskiy mediko-biologicheskiy vestnik. 2012; 15 (23): 134–142. (In Russ.)

[76] Бекезин В.В. Инсулинорезистентность и эндотелиальная дисфункция. Их вклад в развитие метоболического синдрома у детей и подростков. Владикавказский медико-биологический вестник. 2012; 15 (23): 134-142.

[77] Kurshakov A.A., Sayfutdinov R.G., Anchikova L.I. Insulin resistance and endothelial dysfunction in metabolic syndrome. Kazan medical journal. 2011; 92 (2): 173–176. (In Russ.)

[78] Куршаков А.А., Сайфутдинов Р.Г., Анчикова Л.И. и др. Инсулинорезистентность и эндотелиальная дисфункция при метаболическом синдроме. Казанский мед. ж. 2011; 92 (2): 173-176.

RIGHTS & PERMISSIONS

Mustafaeva A.G.